NCT03701737: GOUSAS

Study of Eating Behaviour and Sense of Taste Before and After Treatment With Nocturnal Continuous Positive Airway Pressure in Overweight Patients With Obstructive Sleep Apnea Syndrome.

Completed Last updated 29 September 2023

What this trial tests

trial testing questionnaires in Obesity in 94 participants. Completed in 30 January 2023.

Timeline

25 February 2019

Primary endpoint
30 January 2023

30 January 2023

Quick facts

Lead sponsor	Centre Hospitalier Universitaire Dijon
Status	Completed
Study type	OBSERVATIONAL
Enrollment	94
Start date	25 February 2019
Primary completion	30 January 2023
Estimated completion	30 January 2023
Sites	1 location across France

Drugs / interventions tested

• questionnaires
• wrist actimeter
• Blood samples — full drug profile →

Conditions studied

• Obesity — all drugs for Obesity →
• Obstructive Sleep Apnoea Syndrome — all drugs for Obstructive Sleep Apnoea Syndrome →

Sponsor

Centre Hospitalier Universitaire Dijon

Who can join

18 and older, any sex, with Obesity or Obstructive Sleep Apnoea Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Obstructive sleep apnea (OSA) is characterized by a repeated partial or complete obstruction of the airway that results in a intermittent hypoxia and sleep disturbance.

A complex and reciprocal link between obesity and OSA exists. On the one hand, obesity is one of the main risk factors for OSA. On the other hand, OSA seems to promote obesity. The changes in sleep patterns that characterize OSA alter energy metabolism and promote weight gain. In particular, OSA is associated with metabolic disturbances, decreased physical activity and changes in energy expenditure resulting in weight gain. OSA is characterized by resistance to leptin which reduces the feeling of satiety and an increase in ghrelin levels which increases the feeling of hunger.

There may be an increase in food intake, but very few studies have looked at this aspect. Our current knowledge is based on simple patient reports of the amount of food consumed per 24 hours.

First-line treatment of OSA is based on continuous positive airway pressure (CPAP) but this approach is not curative and weight loss is encouraged. CAPP could facilitate weight loss by restoring sleep quality. Paradoxically, recent studies show weight gain proportional to the duration of use of CPP. Randomized controlled trials offering apneic patients a return to physical activity and hygiene-dietary rules have shown an improvement in OSA after weight loss.

A better understanding of the influence of OSA and its treatment on the energy balance through food preferences and olfacto-gustatory sensoriality is an essential prerequisite for personalized nutritional management. In the face of unexpected weight gain under CPP, this type of intervention would be all the more beneficial as OSA and obesity are public health problems representing two independent risk factors for cardiovascular morbidity and mortality with increasing incidence.

We hypothesize that the treatment of OSA with CPAP changes food preferences in favour of fatty and sugary high-calorie foods.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.